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Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by a
dysregulated Janus kinase (JAK)/signal transducer and activator of transcription
(STAT) pathway that can present as primary MF or evolve from polycythemia vera
or essential thrombocythemia.1-4 Common aspects of the disease include bone mar-
JUMP is a phase 3b expanded-access trial for patients without access toruxolitinib outside of a clinical study; it is the largest clinical trial to datein patients with myelofibrosis who have been treated with ruxolitinib.
Here, we present safety and efficacy findings from an analysis of 1144
patients with intermediate- or high-risk myelofibrosis, as well as a separate
analysis of 163 patients with intermediate-1-risk myelofibrosis – a popula-
tion of patients not included in the phase 3 COMFORT studies. Consistent
with ruxolitinib’s mechanism of action, the most common hematologic
adverse events were anemia and thrombocytopenia, but these led to treat-
ment discontinuation in only a few cases. The most common non-hemato-
logic adverse events were primarily grade 1/2 and included diarrhea, pyrex-
ia, fatigue, and asthenia. The rates of infections were low and primarily
grade 1/2, and no new or unexpected infections were observed. The major-
ity of patients achieved a ≥50% reduction from baseline in palpable spleen
length. Improvements in symptoms were rapid, with approximately half of
all patients experiencing clinically significant improvements, as assessed by
various quality-of-life questionnaires. The safety and efficacy profile in
intermediate-1-risk patients was consistent with that in the overall JUMP
population and with that previously reported in intermediate-2- and high-
risk patients. Overall, ruxolitinib provided clinically meaningful reductions
in spleen length and symptoms in patients with myelofibrosis, including
those with intermediate-1-risk disease, with a safety and efficacy profile
consistent with that observed in the phase 3 COMFORT studies. This trial
was registered as NCT01493414 at ClinicalTrials.gov.
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ABSTRACT
row fibrosis, extramedullary hematopoiesis, anemia,
splenomegaly, a debilitating symptom burden (e.g.,
fatigue, weight loss, night sweats, pruritus),4-7 and reduced
survival.8 Patients are stratified as having low-, intermedi-
ate-1-, intermediate-2-, or high-risk MF by International
Prognostic Scoring System (IPSS) criteria, with correspon-
ding median survivals of 11, 8, 4, and 2 years.8
Ruxolitinib is a potent JAK1/JAK2 inhibitor that has
demonstrated superiority over placebo9 and best available
therapy10 in the pivotal phase 3 COMFORT (Controlled
Myelofibrosis study with Oral JAK inhibitor Treatment)
studies in patients with intermediate-2- or high-risk MF.
Ruxolitinib treatment led to durable improvements in
splenomegaly, symptoms, and quality-of-life (QOL) meas-
ures as well as improved survival.9-11 Based on these find-
ings, ruxolitinib became the first JAK inhibitor approved
for the treatment of MF. Despite the impact of these stud-
ies on the treatment landscape in higher-risk MF, not much
is known about the efficacy and safety of ruxolitinib in
patients with intermediate-1-risk MF – a group that also
has significant constitutional symptoms, splenomegaly,
and a reduced health-related QOL.8 Findings from
ROBUST, a phase 2 study that evaluated ruxolitinib in
patients with high-, intermediate-2-, and intermediate-1-
risk MF, indicated that ruxolitinib treatment results in clin-
ically meaningful reductions in spleen length and symp-
toms in most patients, including those classified as inter-
mediate-1 risk.12
To allow for collection of additional safety and efficacy
data for ruxolitinib and provide an access path to ruxoli-
tinib for patients with MF, the JUMP (JAK Inhibitor
RUxolitinib in Myelofibrosis Patients; NCT01493414)
study was initiated. JUMP is a phase 3b expanded-access
trial for patients in countries without access to ruxolitinib
outside of a clinical study and includes those classified as
intermediate-1 risk, a population that was not included in
the COMFORT trials. Here, we present safety and effica-
cy findings from an analysis of 1144 patients with MF and
163 patients with intermediate-1-risk MF who started rux-
olitinib treatment ≥1 year before the data cut-off.
Methods
Eligibility criteria
Eligible patients were aged ≥18 years with a diagnosis of pri-
mary or secondary MF by World Health Organization criteria3,13
and classified as IPSS high, intermediate-2, or intermediate-1 risk
by the treating investigator.8 Patients with intermediate-1-risk MF
were required to have a palpable spleen (≥5 cm from the costal
margin). However, IPSS risk status was not recorded until imple-
mentation of protocol amendment 2, and most patients did not
have IPSS risk status at the time of this data cut. Patients were
required to have a baseline platelet count ≥50×109/L; those with a
platelet count of 50×109/L to 100×109/L were included through
amendments to the protocol. 
Study design
JUMP is a single-arm, open-label phase 3b expanded-access
global study. Patients received starting doses of ruxolitinib based
on platelet counts at baseline: 5 mg twice daily (bid; 50×109/L to
<100×109/L), 15 mg bid (100 to 200×109/L), or 20 mg bid
(>200×109/L). Doses could be increased (up to 25 mg bid if platelet
and neutrophil counts were adequate) in 5-mg bid increments (5
mg/day for patients starting ruxolitinib at 5 mg bid) when efficacy
was insufficient. Dose decreases or interruptions were mandatory
for safety reasons (e.g., declining platelet counts) and were made
according to a protocol-specified dosing regimen (Online
Supplementary Methods). Patients were followed up for 28 days
after treatment discontinuation. The final analysis will be per-
formed after all patients have completed 24 months of treatment,
unless discontinuation criteria are met (Online Supplementary
Methods).  
Endpoints
The primary endpoint was assessment of ruxolitinib safety and
tolerability by the frequency, duration, and severity of adverse
events. Additional endpoints included the proportion of patients
with ≥50% reduction in palpable spleen length, patient-reported
outcomes [Functional Assessment of Cancer Therapy -
Lymphoma (FACT-Lym) total score (TS) and Functional
Assessment of Chronic Illness Therapy (FACIT) - Fatigue Scale],
progression-free survival, survival without transformation to acute
myeloid leukemia (AML-free survival), and overall survival (Online
Supplementary Methods).
Study oversight
The study was sponsored and designed by Novartis
Pharmaceuticals Corporation, approved by the institutional
review board at each participating institution, and conducted in
accordance with applicable local regulations and the principles of
the Declaration of Helsinki. All patients provided written
informed consent. Data were analyzed and interpreted by the
sponsor’s clinical and statistical teams in collaboration with
authors not affiliated with the sponsor. A publication steering
committee discussed the data and analyses and helped guide the
publication plan for this study. The first author prepared the first
draft of the manuscript, with assistance from a medical writer
funded by Novartis Pharmaceuticals Corporation, and made the
final decision to submit the manuscript for publication. All authors
reviewed and amended the manuscript. 
Statistical analysis
This analysis includes results from patients who started ruxoli-
tinib treatment ≥1 year before the data cutoff. Only descriptive
statistics are provided. Changes in spleen length were assessed in
patients with baseline and post-baseline assessments. A 100%
reduction from baseline in spleen length was defined as non-pal-
pable. Survival assessments were performed at the end of the 28-
day follow-up period. Progression-free and overall survival were
estimated using the Kaplan-Meier method.
Results
Patients
A total of 2233 patients were enrolled at more than 200
study sites in 26 countries (last patient first visit, 23
December 2014). This analysis includes results for 1144
patients who started ruxolitinib treatment ≥1 year before
the data cutoff date (01 January 2014). Patients were from
Europe (83.6%), South America (8.5%), North America
(4.6%), and other regions (3.5%) (Online Supplementary
Table S1). The baseline characteristics of the patients are
shown in Table 1. The median age of the patients was 68
years (range, 18-89 years), with a median time since initial
diagnosis of 36 months (range, 0.1-433.1 months). Overall,
53.3% of patients were male and 58.8% had primary MF.
Most patients completed treatment per protocol (i.e.,
had access to commercially available drug; 33.5%) or
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remained on treatment (35.5%; Online Supplementary Table
S2). The most common reasons for treatment discontinu-
ation included adverse events (13.8%), investigator-deter-
mined disease progression (7.1%), death (3.8%), consent
withdrawal (3.8%), and physician’s decision (1.4%).
Specific adverse events that led to discontinuation are
shown in Online Supplementary Table S3.
The median exposure to ruxolitinib was 11.1 months.
The mean total daily dose over time is shown in Figure 1.
The median average daily dose was 37.2 mg for patients
starting at 20 mg bid (63.6%), 23.4 mg for patients starting
at 15 mg bid (32.7%), and 13.3 mg for patients starting at
5 mg bid (1.0%). The majority of patients (65.9%) had a
dose modification, and 23.9% had a dose interruption. 
Safety
Consistent with findings from the COMFORT stud-
ies,9,10 the most common hematologic adverse events were
anemia (all grades, 56.3%; grade 3/4, 33.0%) and throm-
bocytopenia (all grades, 42.2%; grade 3/4, 12.5%; Table
2). However, only 2.6% (n=30) and 3.2% (n=37) of
patients, respectively, discontinued treatment (Online
Supplementary Table S3), indicating that these adverse
events were manageable in most patients. Overall, 159
patients (13.9%) received erythropoiesis-stimulating
agents as concomitant medication; preliminary results are
summarized for these patients. Similar to what has been
observed previously,9,10 mean hemoglobin levels decreased
from baseline (108 g/L) during the first 8 to 12 weeks of
the study but increased to near-baseline levels after week
12 (Figure 2A). Mean platelet counts decreased from base-
line (319×109/L) during the first 4 weeks and then
remained stable over time (Figure 2B). As expected, the
rates of thrombocytopenia were higher in patients who
had baseline platelet counts of 100×109/L to 200×109/L and
received ruxolitinib at a starting dose of 15 mg bid (all
grades, 58.8%; grade 3/4, 22.2%) than in patients who
had baseline platelet counts >200×109/L and started treat-
ment at 20 mg bid (all grades, 33.9%; grade 3/4, 7.1%).
The rates of anemia were similar in both groups (all
grades, 53.2% versus 57.9%; grade 3/4, 32.6% versus
33.1%, respectively).
Serious adverse events were reported in 32.3% of
patients (n=369). Serious adverse events occurring in >1%
of patients included anemia (4.5%), pneumonia (3.9%),
pyrexia (3.2%), cardiac failure (1.8%), dyspnea (1.7%),
abdominal pain (1.6%), gastrointestinal hemorrhage
(1.4%), thrombocytopenia (1.0%), cardiac atrial fibrilla-
tion (1.0%), and general physical health deterioration
(1.0%). There were no reports of progressive multifocal
leukoencephalopathy. 
The most common non-hematologic adverse events
(occurring in ≥5% of patients) were primarily grade 1/2
(Table 2) and included diarrhea, pyrexia, fatigue, and
asthenia. Rates of non-hematologic grade 3/4 adverse
events were low overall (<2%), except the rate of pneu-
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Table 1. Patients’ baseline characteristics.
                                                                                         All Patients
                                                                                           N=1144
Age, median (range), years                                                      68.0 (18.0-89.0)
≥65 years, n (%)                                                                             701 (61.3)
Male, n (%)                                                                                       610 (53.3)
Time since initial diagnosis, median (range), months      36.0 (0.1-433.1)
MF subtype, n (%)a                                                                                   
PMF                                                                                                    673 (58.8)
PPV-MF                                                                                              279 (24.4)
PET-MF                                                                                              191 (16.7)
Hemoglobin level, median (range), g/Lb                             105.0 (44.0-200.0)
<100 g/L, n (%)                                                                               461 (40.3)
Platelet count, median (range), ×109/Lc                             256.0 (75.0-1910.0)
<100×109/L, n (%)                                                                            16 (1.4)
100 to <200×109/L, n (%)                                                              385 (33.7)
≥200×109/L, n (%)                                                                          738 (64.5)
Prior history of transfusions, n (%)                                            373 (32.6)
Peripheral blasts ≥1%, n (%)d                                                      401 (35.1)
Palpable spleen length, median (range), cme                      13.0 (1.0-43.0)
MF: myelofibrosis; PET-MF: post–essential thrombocythemia myelofibrosis; PMF: pri-
mary myelofibrosis; PPV-MF, post–polycythemia vera myelofibrosis. Note: Patients were
classified as intermediate-1, intermediate-2, or high risk per study entry criteria.
However, International Prognostic Scoring System risk status was not collected until
implementation of protocol amendment 2; 95% of patients (n=1087) had missing risk
status information. a n=1143; b n=1140; c n=1139; d n=1059; e n=1072.
Figure 1. Mean total daily
dosea,b of ruxolitinib. bid: twice
daily; qd: once daily. aIncludes
patients with complete drug
administration dates (n=1141).
b28 patients started at doses
other than 5, 15, or 20 mg bid:
5 mg qd (n=1), 7.5 mg bid
(n=1), 15 mg qd (n=6), 10 mg
bid (n=16), 20 mg qd (n=4).
monia (3.6%), which led to drug discontinuation in six
patients (0.5%) (Online Supplementary Table S3). The rates
of infections were also low; all-grade infections in ≥1% of
patients included nasopharyngitis (6.3%), urinary tract
infection (6.0%), pneumonia (5.3%), bronchitis (4.2%),
herpes zoster (3.6%), influenza (3.0%), upper respiratory
tract infection (2.9%), cystitis (2.5%), gastroenteritis
(1.8%), respiratory tract infection (1.8%), and oral herpes
(1.6%) (Online Supplementary Table S4). Other infections
included tuberculosis in three patients (0.3%) and
legionella pneumonia in one patient (0.1%); no hepatitis B
reactivation was reported.
Efficacy
At weeks 24 and 48, 56.9% and 62.3% of evaluable
patients achieved a ≥50% reduction from baseline in pal-
pable spleen length, respectively (Figure 3A); additionally,
23.9% and 18.2% had 25% to <50% reductions at weeks
24 and 48, respectively. At each assessment, at least two-
thirds of patients had a ≥25% reduction in palpable spleen
length, and approximately 80% had a ≥25% reduction
after week 4. Most patients (69.0%) experienced a ≥50%
reduction in spleen length at any time by week 48 (Figure
3B), and 23.0% had spleens that became non-palpable.
The proportion of patients who achieved a ≥50% reduc-
tion in spleen length at any time by week 48 was similar
for patients with primary or secondary MF (66.9% versus
71.6%, respectively; see the Online Supplementary Results
for additional details). At both weeks 24 and 48, ≥50%
reductions from baseline in palpable spleen length were
achieved by a higher proportion of patients starting treat-
ment at 20 mg bid than by those starting at 15 mg bid
(week 24, 61.8% versus 47.3%; week 48, 68.9% versus
48.7%). Likewise, the proportion of patients who
achieved a ≥50% reduction from baseline in palpable
spleen length at any time was higher in patients who start-
ed treatment at 20 mg bid (73.8% versus 60.1%).
The median time to the first ≥50% reduction in palpable
spleen length was 5.1 weeks (range, 0.1-53.1 weeks). The
Kaplan-Meier estimated probability of maintaining a
spleen response for 24 weeks and 48 weeks was 93%
(95% CI, 91%-95%) and 72% (95% CI, 54%-84%),
respectively. The median duration of spleen response was
not yet reached; 9.8% of patients had a loss of response
(i.e., a return of spleen length to baseline size). Preliminary
results suggest that patients who required concomitant
erythropoiesis-stimulating agents on treatment also had
clinically meaningful spleen responses: 70.1% of evaluable
patients (101/144) who received erythropoiesis-stimulat-
ing agents achieved a ≥50% reduction from baseline in
palpable spleen length at any time.
Clinically meaningful improvements in symptoms were
seen as early as 4 weeks after the start of treatment and
were maintained over time, as evaluated by the FACT-
Lym TS (mean change from baseline was 11.0 at week 4
and 9.4 at week 48; Online Supplementary Figure S2A) and
FACIT-Fatigue scale (mean change from baseline was 3.8
at week 4 and 3.0 at week 48; Online Supplementary Figure
S2B). Approximately 44% to 46% and 46% to 52% of
patients achieved a response (i.e., a minimally important
difference at each time point) in the FACT-Lym TS (Figure
4A) and the FACIT-Fatigue scale (Figure 4B), respectively;
symptom response rates were not affected by ruxolitinib
starting dose. Response rates on the FACT-Lym TS and
FACIT-Fatigue scales were similar when evaluated by MF
subtype (Online Supplementary Figures S3 and S4). Similar
improvements were observed in other QOL question-
naires, with the proportions of patients achieving a
response ranging from 44% to 48% for the FACT-Lym
subscale, 40% to 43% for the FACT-Lym Trial Outcome
Index, and 39% to 42% for the FACT-General TS.
A total of 13 patients developed acute myeloid leukemia
during the study or within 28 days following study discon-
tinuation (Table 3). The estimated probability of AML-free
survival at 48 weeks was 94% (95% CI, 92%-95%; Table
3). The estimated probability of progression-free survival at
48 weeks was 91% (95% CI, 89%-93%). The estimated
probability of overall survival at 48 weeks was 94% (95%
CI, 93%-96%) for the overall JUMP population, with 86
reported deaths (Table 3). Investigator-determined causes of
death on study, regardless of causality, included myelofibro-
sis (n=11), cardiac failure (n=7), cardiac arrest (n=7), pneu-
monia (n=6), septic shock (n=5), multi-organ failure (n=4),
transformation to acute myeloid leukemia (n=4), respirato-
ry failure (n=3), sepsis (n=3), cardiorespiratory arrest (n=3),
gastrointestinal hemorrhage (n=2), peritonitis (n=2), renal
failure (n=1), and general health deterioration (n=2). All
other causes were undetermined or reported for one patient
each. The survival estimate for patients who received ery-
thropoiesis-stimulating agents was similar to that for the
overall population (99%; 95% CI, 96%-100%; deaths,
n=10/159).
H.K. Al-Ali et al.
1068 haematologica | 2016; 101(9)
Table 2. Adverse events regardless of study drug relationship (in ≥5%
of patients)a.
Preferred Term All Patients
N=1144
All Grades, n (%)     Grade 3/4, n (%)
Hematologic adverse events
Anemia 644 (56.3)                    378 (33.0)
Thrombocytopenia 483 (42.2)                    143 (12.5)
Neutropenia 63 (5.5)                        44 (3.9)
Non-hematologic adverse events
Diarrhea 166 (14.5)                      13 (1.1)
Pyrexia 152 (13.3)                      16 (1.4)
Fatigue 148 (12.9)                      15 (1.3)
Asthenia 143 (12.5)                      18 (1.6)
Edema peripheral 105 (9.2)                        8 (0.7)
Headache 105 (9.2)                        4 (0.3)
Dyspnea 101 (8.8)                       22 (1.9)
Abdominal pain 91 (8.0)                        14 (1.2)
Nausea 82 (7.2)                         3 (0.3)
Cough 77 (6.7)                         1 (0.1)
Arthralgia 72 (6.3)                         8 (0.7)
Pain in extremity 72 (6.3)                         8 (0.7)
Nasopharyngitis 72 (6.3)                              0
Urinary tract infection 69 (6.0)                        13 (1.1)
Pruritus 68 (5.9)                         2 (0.2)
Constipation 68 (5.9)                         1 (0.1)
Pneumonia 61 (5.3)                        41 (3.6)
Dizziness 61 (5.3)                         4 (0.3)
Epistaxis 59 (5.2)                         8 (0.7)
aAdverse events are reported for the entire treatment period.
Retreatment after ruxolitinib interruption
Overall, 207 of the 1144 patients had a therapy interrup-
tion of ≥7 days before restarting treatment. Compared
with the overall patient population, this subgroup had a
higher proportion of patients with primary MF (68.1% ver-
sus 58.8%) and hemoglobin level <100 g/L (50.7% versus
40.3%) and a lower median platelet count at baseline
(199.5×109/L versus 256×109/L). Interruptions lasted from 7
to 14 days in 41.1% of patients, 15 to 21 days in 26.6% of
patients, and >21 days in 32.4% of patients. Treatment
interruptions were mostly due to adverse events (92.3%).
Adverse events occurring before treatment interruption
were primarily grade 3/4 anemia (34.8%) or thrombocy-
topenia (33.8%); grade 3/4 adverse events occurring in
>2% of patients included decreased platelet count (8.2%),
pneumonia (4.4%), neutropenia (4.4%), leukopenia
(3.4%), abdominal pain (2.9%), and increased gamma-glu-
tamyltransferase (2.4%). Most patients (67.1%) had only
one interruption. There were no reports of a withdrawal
effect following treatment interruption, and, although
exposure to ruxolitinib was more than three times longer
after restarting treatment, the rates of adverse events
before interruption and after restarting treatment were
similar overall. The median duration of exposure was 1.9
months from baseline to interruption and 6.5 months after
restarting treatment. The mean daily dose was 30.5 mg
prior to treatment interruption and 19.4 mg between
restarting treatment and the end of the follow-up. 
Despite treatment interruption, 68.2% of patients
(133/195) experienced a ≥50% reduction in palpable
spleen length at any time. This was achieved by 77
patients (58%) before ruxolitinib interruption and 56
patients (42%) after restarting ruxolitinib. From spleen
length at restarting treatment, 24% of patients achieved a
further 50% reduction, 9% experienced a spleen length
increase ≥50%, and 67% remained stable in between.
Clinically meaningful improvements in symptoms, as
assessed by the FACT-Lym TS, were observed as early as
week 4 (mean change from baseline, 9.6), with a trend
toward improvement at week 48 (mean change, 6.1). 
Patients with intermediate-1-risk myelofibrosis
JUMP included patients classified as intermediate-1-risk,
a group of patients not included in the COMFORT stud-
ies. Overall, 163 intermediate-1-risk patients who started
treatment ≥1 year before data cutoff were identified;
because risk status was not initially collected on study, a
second, later data cutoff date (01 July 2014) was used. The
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Figure 2. Hemoglobin levels
and platelet counts over time.
(A) Hemoglobin levels over
time. Boxes represent the
upper to lower quartiles and
the bars represent the range;
the line is connected through
the mean values. (B) Platelet
counts over time. Boxes repre-
sent the upper to lower quar-
tiles and the bars represent
the range; the line is connect-
ed through the mean values.
A
B
median age in this cohort of patients was 62 years (range,
25-79 years), with a median time since diagnosis of 17.9
months (range, 0.2-276 months); the median palpable
spleen length at baseline was 12 cm (range, 4-45 cm;
Online Supplementary Table S5). Overall, 21.5% and 8.0%
of patients had hemoglobin <10 g/dL and platelet counts
<100×109/L at baseline, respectively. 
In general, ruxolitinib was well tolerated by intermedi-
ate-1-risk patients. At the time of data cutoff, most
patients had completed the study per protocol (4.3%) or
remained on treatment (76.1%). Reasons for treatment
discontinuation included adverse events (11%), with-
drawal of consent (2.5%), disease progression (2.5%),
investigator’s decision (1.8%), physician’s decision (1.8%),
death (1.2%), and protocol deviation (0.6%). The majority
of patients received starting doses of 20 mg bid (65.0%) or
15 mg bid (23.9%), with a median exposure of 14.4
months (range, 0.1-19.1 months) and a median daily dose
of 30.0 mg/day (range, 6.3-49.4 mg/day). Overall, 64% of
patients had dose modifications and 27% had a dose inter-
ruption (23% due to adverse events).
In this cohort of patients, ruxolitinib demonstrated an
adverse event profile consistent with that previously
reported in intermediate-2- and high-risk patients with
MF. The most common hematologic adverse events were
anemia (all grades, 54.0%; grade 3/4, 24.5%), thrombocy-
topenia (all grades, 40.5%; grade 3/4, 11.0%; Online
Supplementary Table S6). Anemia and thrombocytopenia
led to treatment discontinuation in one patient (0.6%) and
three patients (1.8%), respectively. Similar to what was
observed in the overall JUMP population, mean hemoglo-
bin levels decreased from baseline (118.5 g/L) during the
first 8 to 12 weeks and increased to near-baseline levels
after week 24. Mean platelet counts decreased from base-
line (309.4×109/L) during the first 4 weeks but then
remained stable over time. Rates of non-hematologic
grade 3/4 adverse events were low overall (<2%), with the
exception of asthenia (2.5%; Online Supplementary Table
S6). Adverse events leading to treatment discontinuation
were reported for 11% of patients (n=18). These occurred
in one patient each, with the exception of pyrexia (n=2;
1.2%). Rates of infections were also low: all-grade infec-
tions in ≥5% of patients included herpes zoster (8.0%) and
bronchitis (6.1%). Grade 3/4 infections occurring in more
than two patients included pneumonia and sepsis (both
1.8%). Hepatitis B was reported in one patient (0.6%;
H.K. Al-Ali et al.
1070 haematologica | 2016; 101(9)
Figure 3. Spleen response. (A)
Evaluable patients with a
≥25% decrease from baseline
in palpable spleen length. (B)
Best percent change from
baseline in palpable spleen
length at any time by week 48.
Each bar represents data from
an individual patient. Max:
maximum; min: minimum.
aNote: −100% change is
defined as non-palpable. bOnly
patients with spleen length
assessments at baseline and
at a post-baseline visit were
included in this analysis.
A
B
grade 3/4) and led to treatment discontinuation. No tuber-
culosis was reported in this cohort.
Serious adverse events were reported for 22.1% of
patients. Serious adverse events occurring in >1% of
patients included esophageal variceal hemorrhage and
sepsis (both 1.8%) and bronchopneumonia, cardiac fail-
ure, pyrexia, pneumonia, acute renal failure, respiratory
failure, syncope, and urinary tract infection (1.2% each).
There were no reports of progressive multifocal leukoen-
cephalopathy in this cohort of patients. Overall, there
were three deaths among intermediate-1-risk patients.
Primary causes of death included cardiac failure, sepsis,
and undetermined cause (n=1 each).
Similar to patients with higher-risk MF, the majority of
intermediate-1-risk patients in JUMP experienced clinical-
ly meaningful reductions in spleen size and improvements
in disease-related symptoms. At weeks 24 and 48, 63.8%
and 60.5% of patients achieved a ≥50% reduction from
baseline in palpable spleen length, respectively.
Additionally, 19.6% and 21.0% of patients had 25% to
<50% reductions at weeks 24 and 48, respectively (Online
Supplementary Figure S5A). At each assessment, ≥75% of
patients had a ≥25% reduction from baseline in palpable
spleen length. By week 72, 77.6% of patients had
achieved a ≥50% reduction, including 21% (n=34) with
complete resolution of splenomegaly (Online
Supplementary Figure S5B). The median time to a ≥50%
reduction in palpable spleen length was 4.7 weeks (range,
3.1-60.1 weeks), and the estimated probability of main-
taining a response was 91% (95% CI, 83%-95%) at 48
weeks and 88% (95% CI, 79%-94%) at 60 weeks.
Overall, 9.6% of patients had a loss of response. In con-
trast to what was observed in higher-risk patients, the pro-
portion of patients who achieved ≥50% reductions from
baseline in palpable spleen length at week 24 was similar
between those starting with a ruxolitinib dose of 20 mg
bid and those starting with 15 mg bid (65.2% versus
62.9%, respectively). At week 48, the proportion of
patients who achieved a spleen response was slightly
higher in those who started treatment at 20 mg bid (66.2%
versus 55.9%). However, the proportion of patients who
achieved a ≥50% reduction from baseline in palpable
spleen length at any time was higher in patients who start-
ed treatment at 20 mg bid (81.9% versus 68.4%).
Clinically meaningful improvements in symptoms were
seen as early as 4 weeks after the start of treatment, as
evaluated per the FACT-Lym TS and FACIT-Fatigue scale
(Online Supplementary Figure S6). Approximately 30% to
40% and 34% to 47% of patients achieved a response at
each time point in the FACT-Lym TS and on the FACIT-
Fatigue scale, respectively (Online Supplementary Figure S6).
Improvements were also observed on other FACT-Lym
scales, with the proportion of patients achieving a
response ranging from 30% to 43% for the FACT-Lym
subscale, 23% to 31% for the FACT-Lym Trial Outcome
Index, and 29% to 36% for the FACT-General TS.
Discussion
The JUMP study is the most extensive study in MF and
includes the largest cohort of patients treated with ruxoli-
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Figure 4. Quality of life
responses. (A) Proportion of
patients achieving a response




defined as the upper limit of
the minimally important differ-
ence (FACT-Lym total score,
11.2 points). (B) Proportion of
patients achieving a response
on the FACIT-Fatigue Scale:
FACIT: Functional Assessment
of Chronic Illness Therapy.
aResponse was defined as the
upper limit of the minimally
important difference (FACIT-
Fatigue score, 3 points).
A
B
tinib reported to date. Compared with the COMFORT
studies, the JUMP trial seems to have a slightly older pop-
ulation with a longer evolution of MF prior to study entry
and a greater proportion of patients with primary MF.
Overall, the tolerability of ruxolitinib in JUMP was similar
to that observed in the COMFORT studies.9,10 Consistent
with the mechanism of action of ruxolitinib, the most
common adverse events were anemia and thrombocy-
topenia; however, these adverse events were manageable
and led to treatment discontinuation in only 2.6% and
3.2% of patients, respectively. Although findings are pre-
liminary, concomitant administration of erythropoiesis-
stimulating agents was well tolerated and did not have a
negative impact on the efficacy of ruxolitinib, as was seen
in COMFORT-II.14 The rates of infections in JUMP were
low and the infections were primarily grade 1/2; no new
or unexpected infections were observed. Additionally, no
cases of progressive multifocal leukoencephalopathy were
reported. Herpes zoster (3.6%) and influenza (3.0%) were
the most common viral infections. No hepatitis B reactiva-
tion was reported in the 1144-patient cohort, and one case
was reported in the intermediate-1-risk group of patients.
Prophylaxis for herpes zoster or other infections should be
considered on a case-by-case basis and may vary by region
and local risk. Of the 86 deaths in the overall survival
analysis, 83 were recorded as deaths in the leukemia-free
survival analysis; 13 patients had transformation to acute
myeloid leukemia. However, the limited follow-up for
survival in this study should be taken into consideration.
As observed in other studies with ruxolitinib,9,10,12 the
majority of patients in JUMP experienced clinically mean-
ingful reductions in spleen size and improvements in dis-
ease-related symptoms. 
Ruxolitinib was also generally safe and well tolerated and
provided meaningful reductions in splenomegaly and
symptoms in patients who restarted ruxolitinib after treat-
ment interruption. Consistent with ruxolitinib’s mechanism
of action, hematologic adverse events were the primary
cause of treatment interruptions. In the 207 patients who
restarted treatment after therapy interruption, ruxolitinib
provided reductions in palpable spleen length and symp-
toms prior to and after treatment interruption. After restart-
ing treatment, patients were able to stay on ruxolitinib at a
median dose of ≈10 mg bid, and most patients did not
require another interruption. Rates of adverse events did
not increase after restarting treatment. Additionally, the dis-
continuation rate after restarting treatment was comparable
to that observed in the overall study population. Of note,
there was no evidence of a withdrawal effect after discon-
tinuation of ruxolitinib treatment in this cohort of patients.
JUMP also includes patients with intermediate-1-risk
MF, a risk group that was not included in the COMFORT
studies. Importantly, the IPSS was used to determine prog-
nostic score in this study because at the time the protocol
was released in January 2011, the Dynamic IPSS had only
recently been published (October 2010). As mentioned
previously, the adverse event profile of ruxolitinib in inter-
mediate-1-risk patients was consistent with that previous-
ly reported in higher-risk patients.9,10 Rates of non-hemato-
logic adverse events were similar in both groups of
patients, although those with higher-risk MF reported
higher rates of fatigue (12.9% versus 5.5%). Herpes zoster
reactivation was observed in both groups, with intermedi-
ate-1–risk patients reporting higher rates of reactivation
(8.0% versus 3.6%). Patients with intermediate-1-risk MF
achieved clinically meaningful reductions in spleen size
and symptom improvement consistent with those seen in
intermediate-2- and high-risk patients enrolled in this
study. At week 24, slightly more patients with intermedi-
ate-1-risk MF had achieved a ≥50% reduction from base-
line in palpable spleen length than had patients in the
overall population (63.8% versus 56.9%, respectively); the
rates were similar at week 48 (60.5% versus 62.3%).
Additionally, a similar proportion of patients in each
cohort achieved a ≥50% reduction from baseline in palpa-
ble spleen length at any time (overall population, 69%;
intermediate-1-risk patients, 77.6%). The median time to
a spleen response was also similar (4.7 versus 5.1 weeks).
Likewise, the proportion of patients who achieved clini-
cally meaningful improvements in symptoms (≈30% to
40%) was within the expected range and consistent with
that seen in the overall JUMP population (≈45% to 50%).
These findings support those observed in the UK
ROBUST study12 as well as those from real-world clinical
evidence of ruxolitinib use in patients with lower-risk MF20
and indicate that ruxolitinib is an effective treatment for
patients with intermediate-1-risk disease.
Overall, findings from the JUMP study confirm the effi-
H.K. Al-Ali et al.
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Table 3. Progression-free, leukemia-free, and overall survival estimates.a
First Event, n (%) Patients Probability Estimates Probability Estimates
N=1144 at 24 Weeks (95% CI) at 48 Weeks (95% CI)
Progression-free survivalb 0.95 (0.94-0.96) 0.91 (0.89-0.93)
Total n of events 126 (11.0)
Disease progression 49
Death 77
AML-free survivalc,d 0.97 (0.95-0.98) 0.94 (0.92-0.95)
Total n of events 96 (8.4)
Transformation to AML 13
Death 83
Overall survivald 0.97 (0.96-0.98) 0.94 (0.93-0.96)
Total n of deaths 86 (7.5)
AML: acute myeloid leukemia. aIncludes events that occurred  within 28 days after last dose of study drug. bThe time from first dose to date of progressive disease (by International
Working Group for Myeloproliferative Neoplasms Research and Treatment criteria) or death. Median follow-up, 48 weeks. cThe time from first dose to earliest date of either first bone
marrow blasts ≥20% or first peripheral blood blasts ≥20% for ≥8 weeks or death. dMedian follow-up, 52 weeks. 
cacy and safety of ruxolitinib in the treatment of patients
with MF. Ruxolitinib provided clinically meaningful reduc-
tions in spleen size and symptoms, including for those
patients with intermediate-1-risk disease, with a safety
and efficacy profile consistent with that observed in the
phase 3 COMFORT studies. Furthermore, JUMP is a glob-
al study conducted in a setting that resembles routine clin-
ical practice. Findings from this study will help guide clini-
cians in the management of their patients with MF and
may help shape the current treatment paradigm, ultimate-
ly maximizing the benefits that patients can derive from
treatment. 
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